Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of hematologic malignancies, delivering durable responses in patients with relapsed and refractory cancers.
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
Showcases platform momentum, strategic priorities, and long-term value creation outlook
Fabrication of Second-Generation Acalabrutinib Nanocrystals by Employing the Nano-Edge Method for Improving the Physico-Chemical Properties and Forecasting their In-Silico Pharmacokinetic Behaviour
Acalabrutinib (ACL) is approved by the USFDA and classified as a BCS class II drug, primarily used for treating chronic lymphocytic leukaemia.
Unveiling Anticancer Potential of Imidazo-Pyridine/Pyrazine-Fused bicyclic Heterocycles: Insights From in silico and in vitro Studies
Cancer is a significant global health challenge and the second leading cause of death worldwide, responsible for millions of fatalities annually.
Physiologically Based Pharmacokinetic Model for Clinical Translation and Prediction of Drug Interaction of the Major Kratom Alkaloid, Mitragynine
The opioid crisis presents a significant public health issue and underscores the urgency of developing effective treatments for opioid use disorder (OUD).
Supramolecular Organogels Based on Cinnarizine as a Potential Gastroretentive System: In Vitro and In Silico Simulations
Gastroretentive systems are an interesting option for enhancing the bioavailability of weak bases and poorly soluble drugs.
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
Investor Day on January 21, 2026, to present new product vision and AI solutions
How to Streamline Your DMTA Cycle While Being ADMET Aware From the First Iteration
Drug discovery has always been a balancing act, with scientists constantly striving for ‘Goldilocks’ compounds – the search for molecules that achieve on-target activity, while also avoiding hidden liabilities such as toxicity, poor exposure, or unfavorable pharmacokinetics, can seem insurmountable at times.
Exploration of IVIVC Deconvolution Methods in a PBPK Platform: Case Example with Tofacitinib
Modified-release (MR) drug products are designed to provide controlled drug delivery over time, offering therapeutic and compliance advantages.
Oral Pro‑Transferosome Tablets of Carica papaya Leaf Extract: Box–Behnken Optimization and In Silico Mechanistic Insights for Dengue‑Associated Thrombocytopenia
Carica papaya L. leaf extract has long been recognized for its therapeutic potential in dengue-associated thrombocytopenia through enhancement of platelet production and inhibition of dengue viral proteases.
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
Driving Growth with Integrated Software, Services, and AI-Enabled Ecosystem
Comprehensive PBPK Evaluation of Phenytoin and Indomethacin: Dose, Age, Pregnancy and Drug–Drug Interaction Insights
Understanding the pharmacokinetics (PK) of antiepileptic and anti-inflammatory drugs under different physiological conditions is essential for optimizing therapy.
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
Conference call to be on Thursday, January 8, 2026, at 5 p.m. ET
Descriptor-First Approach for ADMET Prediction in the PolarisHub Antiviral Challenge
The prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties remains a central bottleneck in small-molecule discovery.
Vision, Mission and Values
To improve health through innovative solutions.
Mechanistic Modeling of Intramuscular Administration of a Long-acting Injectable Accounting for Tissue Response At the Depot Site
The tissue response to long-acting injectables (LAIs) suspension injection may impact the product in vivo performance.
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
Validated engines and AI-orchestrated ecosystem align with the emerging regulatory framework
Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data
Model-based meta-analysis (MBMA) informs key drug development decisions by integrating data, published or unpublished, from multiple studies.